Navigation Links
FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents
Date:9/8/2008

BOSTON, Sept. 8 /PRNewswire/ -- FluoroPharma, Inc. announced today that Dr. David Elmaleh, FluoroPharma's founder and Chief Scientific Advisor, will report on two preclinical studies demonstrating the potential of novel Positron Emission Tomography (PET) molecular imaging agents for detection of Alzheimer's disease (AD) and prostate cancer at the World Molecular Imaging Congress, in Nice, France on September 10-13, 2008.

The first study, "Synthesis And Biodistribution Of 2-(2-[18f]Fluoroethyl)-8-Methyl-2,8-Diazaspiro[4,5]Decane-1,3,-Dione ([18f]Fluoro-RS-86), A Muscarinic Acetylcholine Receptor Agonist" describes the synthesis, tissue distribution and pharmacokinetic profile of 18F labeled RS-86, a known M1 muscarinic receptor agonist. FluoroPharma has developed a novel biomarker approach for evaluating the progression of Alzheimer's disease based on targeting acetylcholine receptors' activity in the brain. As explained by Dr. Elmaleh, "Acetylcholine receptors have become a potential therapeutic target for improving cognitive function, since the receptors' function in patients with AD is impaired due to accumulation of amyloid plaque. In conjunction with PET imaging, FluoroPharma's compound may be a novel approach to the diagnosis of AD and other neurological diseases and the evaluation of new therapeutics."

The second study, "Accumulation Of F-18 Labeled Modified Fatty Acid (CardioPET) In Prostate Tumor Cells: A Potential Sensitive Pet Tracer For Prostate Imaging" explores the potential of CardioPET, a fatty acid analog, to detect prostate cancer. CardioPET concentrates in significant amounts in human prostate tumor cells and shows potential as a highly sensitive agent for detecting prostate cancer. Prostate cancer is the most frequently diagnosed and second most lethal malignancy among men in the United States.

"These new molecular imaging approaches complement FluoroPharma's existing cardiovascular clinical programs and warrant further evaluation", says Dr. Kundakovic, FluoroPharma's President. "We look forward to expanding our discovery and development of molecular imaging pharmaceuticals for PET to meet the growing needs in neurology and oncology."

About FluoroPharma

FluoroPharma, Inc., a privately-held molecular imaging company headquartered in Boston MA, engages in the discovery, development and commercialization of proprietary diagnostic imaging products for the PET market. The company's initial focus is the advancement of three imaging agents -- CardioPET, BFPET, and VasoPET -- for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Other products in development include agents for the diagnosis of certain types of cancer and for the diagnosis and treatment of Alzheimer's disease. For more information, please visit http://www.fluoropharma.com.

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the company's need for additional funds, the company's dependence on a limited number of imaging compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. FluoroPharma does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE FluoroPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Society of Interventional Radiology Applauds Reports Uterine Fibroid Embolization Recommendations
2. Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
3. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
4. Previous Claims of siRNA Therapeutic Effects Called into Question by Report in Human Gene Therapy
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
7. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
8. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
9. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
10. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
11. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... -- According to the 2016 report, a ... blood pressure monitoring system market growth. With aging, the ... respond to different pressure rates, leading to hypertension or ... cardiovascular disorders such as heart failure, stroke, coronary artery ... in prevalence each year. WHO estimates that 17 million ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... ... Aimed at nurses and employees in the health care world, this installment ... nursing and health care industry. It also provides insight to the developing trends and ... As the nursing industry is coming out of one of the biggest recessions in ...
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a ... (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the 90 ... their favorite way to cook a hot dog, far outpacing other cooking methods such ...
(Date:5/26/2016)... ... 26, 2016 , ... Cabot Corporation, Pfizer, and 3M are ... court documents and SEC filings. A jury has returned a verdict of ... Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 million ...
(Date:5/26/2016)... ... 26, 2016 , ... Georgia State University College of Law ... , Answering to the increasing demand for curricular specializations, the Certificate in Intellectual ... and land use law. ,  , “The demand for lawyers with specific knowledge ...
Breaking Medicine News(10 mins):